SubsidieMeestersAn innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding
PlasFree is developing ClearPlasma™, a filtration system that extracts plasminogen to improve haemorrhage treatment and reduce plasma unit requirements, aiming for clinical validation and global impact.
Projectdetails
Introduction
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleeding and death.
Project Overview
PlasFree is tackling this unmet demand for novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding.
Benefits of ClearPlasma™
ClearPlasma™ also allows for a reduction of up to 45% in the number of plasma units required during transfusion.
Market Potential
PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion.
Goals and Impact
With the EIC support, PlasFree aims to deliver substantial global impact for patients and healthcare systems by:
- Accelerating the development of ClearPlasma™
- Scaling up the production
- Conducting clinical validation to prove the device’s safety and efficacy.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.279.184 |
| Totale projectbegroting | € 1.827.406 |
Tijdlijn
| Startdatum | 1-2-2022 |
| Einddatum | 31-7-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- PLAS-FREE LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
To deliver the first medical treatment dedicated to patients with haemorrhagic strokeNANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Advanced Sterilization Capability with Low Environmental footprint for Patient Infection Optimized SafetyAURORA's ASCLEPIOS project aims to commercialize a novel non-thermal plasma sterilization technology for medical devices, enhancing patient safety and environmental protection while boosting production capacity. | EIC Accelerator | € 2.499.139 | 2023 | Details |
A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThrThe RECOFIB platform produces customized, high-purity recombinant fibrinogen and thrombin from CHO cells, enabling innovative medical applications and reducing reliance on blood plasma. | EIC Accelerator | € 2.500.000 | 2022 | Details |
To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
NANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke.
Advanced Sterilization Capability with Low Environmental footprint for Patient Infection Optimized Safety
AURORA's ASCLEPIOS project aims to commercialize a novel non-thermal plasma sterilization technology for medical devices, enhancing patient safety and environmental protection while boosting production capacity.
A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr
The RECOFIB platform produces customized, high-purity recombinant fibrinogen and thrombin from CHO cells, enabling innovative medical applications and reducing reliance on blood plasma.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
HADRIEHet HADRIE-project ontwikkelt een thuisgebruik versie van het PLASOMA koud plasma systeem om chronische wonden effectiever en op grotere schaal te behandelen. | Mkb-innovati... | € 332.640 | 2018 | Details |
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactorThe project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions. | EIC Transition | € 1.798.152 | 2022 | Details |
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppenSTOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners. | Mkb-innovati... | € 335.944 | 2016 | Details |
PEDRIE: Wondgenezing met koud plasma pad en koud plasma pulserDit project ontwikkelt een kosteneffectief, pijnloos systeem voor de behandeling van diabetische voetzweren met koud-plasmatechnologie, gericht op verbetering van genezing en verlaging van zorgkosten. | Mkb-innovati... | € 349.230 | 2016 | Details |
Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill NewbornsThe ArtPlac project aims to revolutionize newborn care by developing a compact artificial placenta to reduce neonatal deaths and long-term complications through less invasive support. | EIC Pathfinder | € 4.229.608 | 2023 | Details |
HADRIE
Het HADRIE-project ontwikkelt een thuisgebruik versie van het PLASOMA koud plasma systeem om chronische wonden effectiever en op grotere schaal te behandelen.
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor
The project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions.
STOPtheBLEED – Ontwikkeling van unieke combinatie van stollingsfactoren en gelatine particles om ernstige bloedingen veroorzaakt door trauma te stoppen
STOPtheBLEED ontwikkelt een innovatief hemostaseproduct voor het snel en effectief stoppen van ernstige bloedingen door trauma, gericht op gebruik door niet-medische hulpverleners.
PEDRIE: Wondgenezing met koud plasma pad en koud plasma pulser
Dit project ontwikkelt een kosteneffectief, pijnloos systeem voor de behandeling van diabetische voetzweren met koud-plasmatechnologie, gericht op verbetering van genezing en verlaging van zorgkosten.
Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill Newborns
The ArtPlac project aims to revolutionize newborn care by developing a compact artificial placenta to reduce neonatal deaths and long-term complications through less invasive support.